Abstract 250P
Background
Treatment for cervical cancer can significantly affect a patient’s quality of life. The purpose of this research: to study the quality of life in patients with cervical cancer and to analyze the dependence of the quality of life indicators on radiation doses obtained when living in areas adjacent to the Semipalatinsk test site.
Methods
In this study, a survey was conducted of 20 patients (women aged 27 to 70 years, average age 52 years) who received chemoradiation therapy. The questionnaire to assess the quality of life, carried out after treatment, using the official versions of questionnaires EORTC QLQ-CX24. The QLQ-CX24 module includes functional and symptomatic scales. The assessment of individual radiation doses received while living in areas exposed to radioactive exposure was carried out in accordance with official guidelines.
Results
The results obtained for functional scales: overall quality of life 78.4 ± 15.2, body image 80.2 ± 15.3, sexual activity 20.4 ± 19.5, sexual satisfaction 52.4 ± 18.3, sexual/vaginal functioning 42.6 ± 19.8 points. For symptomatic scales: symptoms 15.6 ± 12.8, lymphadenoma 12.9 ± 15.4, peripheral neuropathy 23.9 ± 14.7, menopausal symptoms 33.3 ± 28.4, sexual anxiety 32.4 ± 22.5 points.
Individual radiation doses received by patients while living in radioactively contaminated territories range from 1.06 to 36.11 cSv. For the study group, the relationship between indicators of quality of life and individual radiation doses have not been established. It is impossible to unequivocally affirm the absence of this dependence due to the insufficient number and heterogeneity of the studied group in a number of parameters.
Conclusions
A sufficiently high scale value indicates the overall quality of life reflects a good level of functioning. The rather low levels of the scales of symptoms, lymphedema, peripheral neuropathy indicate the severity of this symptomatology during preventive exposure to PALS. For the study group, the relationship between indicators of quality of life and individual radiation doses have not been established.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
260P - A phase I study of copanlisib, a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, in Chinese patients with relapsed indolent non-Hodgkin lymphoma (iNHL)
Presenter: Yuqin Song
Session: e-Poster Display Session
261P - Clinical outcomes of early-progressed follicular lymphoma in Korea: A multicenter, retrospective analysis
Presenter: Jun Ho Yi
Session: e-Poster Display Session
262P - Correlation between phosphorylated pI3K expression, phosphorylated AKT, and phosphorylated MTOR with serum dehydrogenase lactate level in non-Hodgkin lymphoma
Presenter: Hary Gustian
Session: e-Poster Display Session
263P - Good response to chemotherapy in primary CNS lymphoma may not translate into significant neurocognitive improvement in comatose patients
Presenter: Ryan Lim
Session: e-Poster Display Session
264P - Treatment outcome of primary testicular lymphoma patients treated in tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
271P - Cost-effectiveness of pembrolizumab as monotherapy or in combination with chemotherapy versus EXTREME regimen for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Taiwan
Presenter: Cheng Hsu Wang
Session: e-Poster Display Session
272P - Early metabolic changes in PET metrics over initial 8 weeks of treatment in patients with advanced head neck squamous cell carcinomas treated with chemotherapy
Presenter: Ashish Vaidya
Session: e-Poster Display Session
273P - Long term outcomes of locally advanced & borderline resectable esthesioneuroblastoma and sinonasal tumour with neuroendocrine differentiation treated with neoadjuvant chemotherapy
Presenter: Vikas Talreja
Session: e-Poster Display Session
274P - Comparing comorbidity indices in predicting 90-day mortality after radical radiotherapy for head and neck cancer
Presenter: Therese Tsui
Session: e-Poster Display Session
275P - Weekly paclitaxel, carboplatin and cetuximab (PCC) combination followed by nivolumab in platinum-sensitive recurrent and /or metastatic squamous cell carcinoma of head and neck: A double institution retrospective analysis from India
Presenter: Vivek Agarwala
Session: e-Poster Display Session